Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston

Conference Reports for NATAP


Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston

	HIV and Cardiovascular Disease: Report back from 2016 Conference on Retroviruses and Opportunistic Infections - by Priscilla Hsue MD Professor of Medicine, UCSF - (04/04/16) CROI 2016: Antiretroviral therapy and other interesting observations - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/28/16) HIV Prevention at CROI 2016 - Jared Baten MD, Connie Celum MD - Conference on Retroviruses and Opportunistic Infections Seattle, WA, USA February 22-25, 2016 Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/23/16) Summary from CROI 2016 for Hepatitis C Feedback from real-life: how is HCV therapy working outside of clinical trials? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany Correspondence: Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany - (03/23/16) Clinical Pharmacology at CROI 2016: TAF, PrEP- TDF-Bone, TAF (vaginal, rectal), Maraviroc, Dapivirine Vaginal Ring, Long-Acting ARTs, Peds - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (03/18/16) Update from CROI 2016: Bones, Vitamin D, Frailty - Todd T. Brown, MD, PhD Associate Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (03/17/16) Impressions from CROI - Pablo Tebas, MD University of Pennsylvania. (03/07/16) CROI 2016 Co-morbidities in HIV: Stroke, Cancer, Liver Disease David H Shepp, MD Associate Professor of Medicine Hofstra-Northwell School of Medicine Manhasset, NY - (03/05/16) CROI Summary Report by Eric Daar, MD for NATAP 23rd Conference on Retroviruses and Opportunistic Infections - February 22-25, 2016 Boston, Massachusetts Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/05/16) The Kidney Report - CROI 2016 - Christina Wyatt MD Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (02/26/16) Changes in markers of T-cell Senescence and Exhaustion With HIV Therapy - (02/21/20) A Long-Acting Biodegradable Subcutaneous Implant for Tenofovir Alafenamide Fumarate HIV PrEP - (01/31/17) Early Evidence of Antiviral Activity and Safety of ABX464 in HIV Treatment-Naïve Patients - (10/19/16) Unexpectedly High Rate of Intolerance for Dolutegravir in Real Life Setting - (10/08/16) Traditional and Viral Factors Associated With Iohexol-Based GFR Slope Over 3 Years - (09/20/16) Aging & Comorbidities CROI 2016 - (08/12/16) Effect of CMV and HIV replication on T cell exhaustion and senescence during ART - (06/13/16) Persistent elevation of inflammation markers in HIV+ persons with Cytomegalovirus disease - (06/13/16) sCD163 increase in HIV/CMV coinfected subjects included in ICONA Cohort .. ..."implicated in the accelerated development of vascular and neurological disease in general population - (06/13/16) Increasing PrEP Use among Men who Have Sex with Men, New York City, 2013-2015 - (06/07/16) Early Adopters and Incident PrEP Prescribers in a Public Health Detailing Campaign - (06/07/16) Early Markers of Renal Dysfunction Among Cocaine Users With HIV and HCV Infection - (05/17/16) Understanding the Relative Contributions of IDU and HCV on Systemic Immune Activation...... .....HCV should be aggressively treated in current IDUs even more if HIV and/or HCV positive - (04/4/16) HCV at CROI 2016 - (04/4/16) ARTs & Mitochondrial toxicity......AZT/NNRTI induces greater adipose tissue mitochondrial toxicity than AZT/PI...... These findings support emerging data on NNRTIs contribution to thymidine-NRTI toxicity, suggesting additive MtTox as an underlying mechanism. - (04/4/16) Differences in Predictors for Ischaemic and Haemorrhagic Strokes in HIV+ Individuals - (04/4/16) Stroke in HIV-infected patients in the combination antiretroviral therapy era - (04/4/16) Gender and Racial Disparities in Initial Antiretroviral Treatment Outcome: ACTG A5257 - (04/4/16) Reduced Ovarian Reserve Relates to Monocyte Activation and Subclinical Coronary Atherosclerotic Plaque in Women with HIV - (04/4/16) Hepatitis C and the Risk of Non-Liver-Related Morbidity and Mortality in HIV+ Persons....kidney, bone, cardiovascular - (04/4/16) CROI: [2 studies] HIV Viral Load in US Clinics Over Time: Trends and Predictors from CNICS - (03/31/16) Liver Fibrosis Linked to Cognition in HIV and HCV: The Women's Interagency HIV Study - (03/29/16) Persistently Increased Ischemic Stroke Risk in HIV-Infected Women - (03/29/16) Comparing Cardiovascular Disease Risk Scores for Use in HIV-Infected Individuals.......Optimal cardiovascular disease risk score for HIV - (03/29/16) Effect of T-Cell Activation on Endothelial Dysfunction in HIV - (03/29/16) Differences by HIV Serostatus in Coronary Artery Disease Severity following Stress Testing - (03/29/16) Diastolic Function Correlates With Pericardial Fat [fat around the heart] and Vascular Remodeling in HIV - (03/29/16) Statin Effects on oxLDL in Relationship to Plaque and Arterial Inflammation in HIV.....statin reduced LDL - (03/29/16) Myocardial Infarction Risk in the NA-ACCORD Compared to MESA and ARIC - (03/29/16) Design, implementation, and findings of next generation stroke adjudication in HIV - (03/29/16) Impact of Depression on Mortality, Viral Load, and Adherence: Three CROI Studies - written by Mark Mascolini (03/29/16) - NNRTI-resistant Mutants Are Suppressed by Doravirine at Clinically Relevant Concentrations - (03/28/16) Aspirin fails to impact immune activation or endothelial function in treated HIV - (03/28/16) HIV DNA Identified in Most Tissues of a Plasma Negative HIV Autopsy Cohort - (03/28/16) Safety and Efficacy of E/C/F/TAF in HIV-1-Infected Treatment-Naïve Adolescents - (03/28/16) Increased HIV Viral Suppression Among US Adults Receiving Medical Care, 2009-2013 - (03/28/16) Immunologic Effects of Maraviroc vs. Tenofovir and Associations with Bone Loss - (03/28/16) What exactly does antiretroviral therapy do to bone? Plenary on Bone at CROI By Paddy Mallon - (03/28/16) Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women (ASPIRE) - (03/28/16) Mitochondrial DNA Copy Number and Neurocognitive Impairment in HIV-Infected Persons....."mtDNA associated with worse cognitive outcomes".....both HIV & ART duration associated with mtDNA damage - (03/28/16) Compartmentalized HIV DNA Populations Persist in CSF Despite Suppressive ART - (03/28/16) MVC and TDF Reduce Neurocognitive Impairment in Initial ART - (03/28/16) Hepatitis C in Egypt: A National Approach to Treatment, Manal El-Sayed MD - (03/24/16) Real-life renal safety of "boosted TDF" in HIV/HCV-patients on SOF/LDV - (03/24/16) HCV resistance to the daclatasvir/sofosbuvir combination across different HCV genotypes in the real life French Cohort - (03/24/16) Lower Ribavirin Exposures in HIV+ Patients that Relapsed to Acute HCV Treatment: SWIFT-C - (03/24/16) Response to DAA-based regimens in HIV-HCV co-infected patients in real-life, France....patients with avg Fibroscan of 14.2 kPa / 67% of patients cirrhotic - (03/24/16) SOF/Rbv SWIFT-C Study Acute HCV Treatment: low RBV levels & relapse; Acute HCV - studies of 4, 6, 8 & 12 weeks - (03/23/16) MVC and TDF Reduce Neurocognitive Impairment in Initial ART - (03/21/16) New HIV Drugs (ARTs): prevention/treatment..... - (03/21/16) Is Intensive Cervical Cancer Screening Justified in Immunosuppressed Women? - (03/21/16) Directly Acting Agents Against HCV - Results From the German Hepatitis C Cohort (GECCO) in HIV+, 8 weeks SOF/LDV - (03/18/16) HCV in Egypt: History/Epidemiology, Care/Access/Treatment.... more than 90% Egyptian HCV is genotype 4 - (03/18/16) SOF/Rbv SWIFT-C Study Acute HCV Treatment: low RBV levels & relapse; Acute HCV - studies of 4, 6, 8 & 12 weeks - (03/18/16) Vitamin D Supplementation Decreases Immune Activation and Exhaustion in HIV+ Youth...high dose did best & increased Vit D levels best too - (03/17/16) Immunopathogenesis of Metabolic Complications in Treated HIV Infection - (03/15/16) Belly Fat (lipodystophy) May be Caused by Metabolic Abnormalities: immune activation/inflammation/senescence - (03/14/16) Adipose Tissue [belly, subcutaneous] and HIV infection - (03/14/16) Frailty In HIV-infected Patients Is Associated With Increased Insulin Resistance - (03/14/16) Tenofovir and the Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Persons - (03/14/16) TAF / PrEP - TDF, TAF, Cabotegravir - Cabotegravir+Rilpivirine - LATTE-2, Maravoric / Dapivrine Vagnal Ring - Tenofovir Rectal / Long-Acting - MK-8591 Long Acting - BMS-986197 - (03/14/16) Complications & It's Immunopathogenesis - (03/14/16) "Chemsex" and High-Risk Sexual Behaviours in HIV-Positive Men Who Have Sex With Men...increased risk for HCV & STIs - (03/14/16) Efavirenz Is Associated With Higher Bone Mass in South African Children With HIV....after switching to EFV from LPV/r - (03/14/16) Duration of in utero exposure to tenofovir and linear growth in the first year of life - (03/14/16) P1084s: Impact of maternal tenofovir disoproxil fumarate (TDF) use on HIV-exposed newborn bone mineral content - (03/14/16) Effects of Vitamin D Supplementation on BMD and Bone Markers in HIV+ Youth - (03/14/16) Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons - (03/14/16) Maternal TDF Does Not Affect Infant Bone Mineral Content in Africa - Mark Mascolini (03/14/16) Fractures Occur at a Younger Age in HIV+ Men in the Multicenter AIDS Cohort Study - (03/14/16) "Chemsex" and High-Risk Sexual Behaviours in HIV-Positive Men Who Have Sex With Men...increased risk for HCV & STIs - (03/11/16) Sexual Behaviour is Associated with Recently Acquired HCV in HIV/HCV Co-infected MSM - (03/11/16) Prevalence & Factors of HCV Infection Among HIV-Negative & HIV-Positive MSM - (03/11/16) Incidence of Hepatitis C Virus Infection in the HIV Outpatient Study (HOPS) Cohort: 2000-2013.... from 2011-2023 MSM HCV hazard ratio was 4.5 times greater vs IDUs (Table 2) - (03/11/16) Hepatitis C Screening and Linkage to Care [Cascade of Care] at a Comprehensive Health System (Detroit/Henry Ford health System)...78% not screened for HCV - (03/11/16) Residual risk of disease progression after hepatitis C cure in HIV-HCV co-infected patients - (03/11/16) Liver Cancer in Patients Cured of HCV: Less Cirrhosis and Less Fat than Expected - (03/11/16) Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance - (03/11/16) HCV Treatment in Groups at Risk for Reinfection - talk at CROI by Oluwaseun Falade-Nwulia - (03/11/16) Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons - (03/10/16) Prevalence of Falls among Older Women in the Women's Interagency HIV Study - (03/10/16) Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy - (03/10/16) Low ART Adherence Is Associated With Higher Inflammation Despite HIV Suppression.......Wobbly ART Adherence Could Fuel Ongoing Inflammation - (03/10/16) Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy - (03/09/16) Adherence Predicts Failure on PI-Based Second-Line ART in Rural South Africa ....High Rate of non-adherence in 1st & 2nd Line ART...."implications for Universal ART" - (03/09/16) Racial Differences in Bioavailable Vitamin D and Response to Supplementation: A5280 ...... Bone, Vit D, EFV+Truvada & Blacks - (03/09/16) Aging/HIV IGNORED....The aging survivors left behind by AIDS - (03/09/16) Metabolic Alterations and Physical Function in Older HIV-Infected Adults.....Older HIV-infected persons have diminished physical performance compared to HIV-uninfected controls / Aging at CROI - (03/09/16) 1970s HIV-1 Genomes Reveal the Early History of the North American HIV/AIDS Epidemic - (03/09/16) Concentrations of TFV and TFVdp in Female Mucosal Tissues After a Single Dose of TAF - (03/08/16) Cancer versus tuberculosis mortality among HIV-infected Individuals in Botswana...... cancer mortality likely exceeds mortality due to tuberculosis - (03/08/16) Excess Mortality Among HIV-Infected Cancer Patients in the United States ....excessive breast cancer mortality found in young non-White females 30-49 & 50-69 years old Table 1) - (03/08/16) Quarterly STI Screening Optimizes STI Detection Among PrEP Users in the Demo Project - (03/08/16) STI Data from Community-Based PrEP Implementation Suggest Changes to CDC Guidelines - (03/08/16) Changes in Renal Function Associated with TDF/FTC PrEP Use in the US Demo Project - (03/08/16) Maraviroc induces HIV production in a RCT and in vitro, potentially via the NF-kB pathway - (03/08/16) A Quantitative Model of ART Efficacy Explains the Clinical Success of Dolutegravir - (03/08/16) INSTI In-class Switching on Continued Viral Suppression in the OPERA Cohort - (03/08/16) Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women - (03/08/16) Pharmacokinetics, Safety and Efficacy of Maraviroc in Pediatric Patients With R5 HIV - (03/08/16) Tolerability and Acceptability of Cabotegravir LA Injection: Results From the ECLAIR Study - (03/08/16) Comparable Viral Decay in Dual and Triple Dolutegravir-Based Antiretroviral Therapy - (03/08/16) 2 Dapivirine Vaginal Ring Studies - (03/07/16) The Renal Impact of Tenofovir Disoproxil Fumarate in the NA-ACCORD - (03/07/16) Changes in CVD Risk Factors with Immediate and Deferred ART in the START Trial - (03/07/16) Persistent HIV-1 in the CNS during therapy: evidence of a viral reservoir in the CNS - (03/07/16) NEW RECOMMENDATIONS IN THE UPDATED WHO: GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION - (03/07/16) Ledipasvir/Sofosbuvir Controls Acute HCV in HIV+ Without Highest HCV Loads - Mark Mascolini (03/07/16) Project INSPIRE: a Comprehensive Care Coordination Program for HCV-Infection Preliminary Year 1 Results - (03/07/16) HCV Guidelines Updated Feb 24 2016 - (03/07/16) Resistance Associated Variants: Data From the NIAID SYNERGY Trial / Harvoni-Retreating Short Duration Therapy - (03/07/16) Immediate ART Initiation Reduces Risk of Infection-Related Cancer in HIV Infection/START Study - (03/07/16) Ledipasvir/Sofosbuvir Controls Acute HCV in HIV+ Without Highest HCV Loads - Written by Mark Mascolini (03/07/16) Abacavir (ABC) use and risk of recurrent myocardial infarction (MI) - (03/05/16) Pooled Week-48 Analysis of HIV-1 Drug Resistance in E/C/F/TAF (Genvoya) Phase 3 Studies - (03/05/16) Durable Viral Suppression Among HIV-diagnosed Persons - United States, 2012-2013....38% are nor durably suppressed - (03/05/16) Ravidasvir/Sofosbuvir Yields Quick SVRs in Largest Genotype 4 Trial - (03/05/16) Statin Dose and Type Tied to Lower Fibrosis Progression and Liver Cancer Incidence - (03/05/16) TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r + Dasabuvir + RBV for HCV/HIV Co-Infection - (03/05/16) Safety and Tolerability of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (03/05/16) CROI 2016 - Themed Discussion: Rants About HCV RAVS - (03/05/16) Retreatment of HCV/HIV-Coinfected Patients Who Failed 12 Weeks of LDV/SOF - (03/05/16) High HCV Cure Rates for Drug Users Treated with DAAs at an Urban Primary Care Clinic - (03/05/16) IMPAACT 1093: Dolutegravir in 6-12 Year Old HIV Infected Children: 48-Week Results ........Dolutegravir Effective and Safe in ART-Experienced 6- to 12-Year-Olds - Mark Mascolini - (03/03/16) Almost 40% of HIV+ People in Care in US Have Detectable Viral Load - Mark Mascolini - (03/03/16) Incidental Carotid Plaque in HIV and an increase in subsequent Cerebrovascular Events.....Carotid Plaque Develops More Often With HIV and Triples Stroke Risk - Mark Mascolini - (03/03/16) Low CD4s, High Viral Load Tied to Progression to Advanced Liver Fibrosis - Mark Mascolini - (03/03/16) Body composition changes on Darunavir/Ritonavir (DRV/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as first-line antiretroviral therapy. NEAT 001/ANRS 143. Body composition sub-study - Mark Mascolini - (03/03/16) First Look at Big 75-and-Older HIV Group--Diagnosed at Age 62.....much higher rates of comorbidities among older HIV+ - 40% with 2 or more, 14% with 4 or more comorbidities - Mark Mascolini - (03/03/16) HIV Suppression Rate Rose Significantly in US From 2009 to 2013 - Mark Mascolini - (03/03/16) Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% - Mark Mascolini - (03/03/16) Paroxetine and fluconazole therapy for HAND: a double-blind, placebo-controlled trial .....New Brain Treatment: Cognitive Gains With Paroxetine in Randomized Trial of HAND Patients - Mark Mascolini - (03/03/16) Large Trial Finds Little Benefit in HPV Vaccine for Older HIV+ Adults - Mark Mascolini - (03/03/16) Immediate ART for All Still a Long Way Off in France--and Elsewhere - Mark Mascolini - (03/03/16) Intensive Cervical Cancer Screening Needed Only at Lower CD4s in HIV+ Women - Mark Mascolini - (03/03/16) Avoiding HCV, HBV, Alcohol Abuse Could Avert Up to One Third of ESLD Cases With HIV - Mark Mascolini - (03/03/16) Under Half in US Analysis Get Resistance Testing at Linkage to Care - Mark Mascolini - (03/03/16) Following ACC/AHA Guidelines Will Undertreat Atherosclerosis in HIV Patients - Mark Mascolini - (03/03/16) Each Delayed Month in Starting ART Could Trim CD4 Tallies Substantially - Mark Mascolini - (03/03/16) Dolutegravir Effective and Safe in ART-Experienced 6- to 12-Year-Olds - Mark Mascolini - (03/03/16) Renal Safety of Tenofovir Alafenamide in Patients at High Risk of Kidney Disease - (03/05/16) Longer-Term Safety of Tenofovir Alafenamide in Renal Impairment - (03/01/16) Longer-Term Renal Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate - (03/01/16) Ledipasvir/Sofosbuvir for 6 Weeks in HIV-Infected Patients with Acute HCV Infection - (03/01/16) Interactions Between ABT-493 plus ABT-530 combination and Rilpivirine or Raltegravir - (03/01/16) Protective Effect of Coffee Intake on Mortality of French HIV-HCVInfected Patients (ANRS CO13 HEPAVIH Cohort) - (03/01/16) Atorvastatin and Fluvastatin are Associated with Dose-Dependent Reductions in Cirrhosis and HCC Among Patients with HCV: Results from ERCHIVES - (03/01/16) Poorly Controlled HIV Infection is a Risk Factor for Liver Fibrosis in the CNICS Cohort ...CD4 & Viral load predict progression to advanced fibrosis - (03/01/16) Body composition changes on Darunavir/Ritonavir (DRV/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as first-line antiretroviral therapy. NEAT 001/ANRS 143. Body composition sub-study - (02/29/16) Aging with HIV: Emerging importance of chronic comorbidities in patients over 75 - (02/29/16) Frailty is associated with NNRTI-based Initial ART and Modifiable Risks in ACTG 5322 - (02/29/16) Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults - (02/29/16) Trends in Comorbid Conditions Mentioned with HIV Disease on Death Certificates, United States, 2000-2010 ...Comorbidities' Deaths Sharply Increasing/Leaders Ignore Problem - (02/29/16) HIV Combinectin BMS-986197: A long-acting inhibitor with multiple modes of action - (02/29/16) A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women - (02/29/16) Chemoprophylaxis with Oral FTC/TAF Protects Macaques from Rectal SHIV Infection - (02/29/16) PrEP Impact on T cell Activation and Explant Infection...HPTN 069/ACTG 5305 Substudy - (02/29/16) MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel - (02/29/16) ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir - (02/29/16) Early Antiretroviral Therapy Does Not Improve Vascular Function: A START Substudy - (02/29/16) ACTG A5298: A Phase 3 Trial of the Quadrivalent HPV Vaccine in Older HIV+ Adults - (02/26/16) HIV-1 Infection With Multiclass Resistance Despite Preexposure Prophylaxis (PrEP) - (02/26/16) Cardiovascular Biomarkers After Switching to ABC/DTG/3TC: The STRIIVING Study - (02/26/16) STROKE INCIDENCE HIGHEST IN WOMEN AND BLACK HIV-INFECTED PARTICIPANTS IN ALLRT COHORT - (02/26/16) Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 96 Analysis - (02/26/16) Doravirine 100 mg QD vs Efavirenz +TDF/FTC in ART-Naïve HIV+ Patients: Week 48 Results - (02/26/16) It's Complicated: Renal Function & STIs in PrEP Users / Themed Discussion at CROI - (02/26/16) Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function - (02/26/16) HPTN 069 / ACTG A5305 Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in Men Who Have Sex With Men (MSM) - (02/26/16) Cabotegravir Long-Acting Injection Protects Macaques against Intravenous Challenge - (02/26/16) Depression and Social Isolation Mediate Effect of HIV Stigma on Women's ART Adherence - (02/26/16) Switching tenofovir DF to tenofovir alafenamide in virologically suppressed adults....TAF/FTC Noninferior to TDF/FTC, and Safer, in Switch Study - Mark Mascolini - (02/25/16) Tenofovir Rectal Gel Safe and Acceptable in Study of MSM and TGW - Mark Mascolini - (02/25/16) Injected Long-Acting Cabotegravir Protects Macaques From Injected SIV - Mark Mascolini - (02/25/16) Early Antiretroviral Therapy Does Not Improve Vascular Function: A START Substudy - Mark Mascolini - (02/25/16) One in 64 in US--Including 1 in 2 Black MSM--Will Get HIV in Their Lifetime - Mark Mascolini - (02/25/16) 9-YEAR TRENDS IN NON-LIPID CARDIOVASCULAR DISEASE PREVENTION STRATEGIES IN HIV+ WOMEN in WIHS-women have poor control of diabetes & hypertension - Mark Mascolini - (02/25/16) Poor HIV Control, Black Race, Female Sex Boost Stroke Risk in US Cohort - Mark Mascolini - (02/25/16) Increasing Hypertension and Diabetes Rx for HIV+ Women, But Poor Control - Mark Mascolini - (02/25/16) HIV Keeps Evolving in Cancer Tissues and Other Tissues During Suppressive ART - Mark Mascolini - (02/25/16) ACTG A5340: the effect of VRC01 on viral kinetics after analytical treatment interruption .........VRC01, a Broadly Neutralizing Antibody, Does Not Maintain HIV Control When ART Stops - Mark Mascolini - (02/25/16) Body composition changes on Darunavir/Ritonavir (DRV/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as first-line antiretroviral therapy. NEAT 001/ANRS 143. Body composition sub-study.......Bigger Trunk Fat Gains With Raltegravir Than TDF/FTC (Both With DRV/r) - Mark Mascolini - (02/25/16) Narrowing the gap in life expectancy for HIV+ compared with HIV- individuals...Life Expectancy Gap Between HIV+ and HIV- Narrows But Persists - Mark Mascolini - (02/25/16) Antiretrovirals, fractures and osteonecrosis in a large European HIV cohort - EuroSIDA........TDF Is Only Antiretroviral Implicated in EuroSIDA Fracture Study - Mark Mascolini - (02/25/16) Perception of Infectiousness in HIV-infected persons after initiating ART: ACTG A5257.......Few on ART in ACTG Analysis Think They Cannot Transmit HIV - Mark Mascolini - (02/24/16) Repeated TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Viral Remission - (02/24/16) Three Maraviroc PrEP Regimens Largely Protective in US MSM Study - Mark Mascolini - (02/24/16) Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys - (02/24/16) ECLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men.......Long-Acting Cabotegravir Data Suggest PrEP Injections Every 8 Week - Mark Mascolini - (02/24/16) More Coffee Tied to Lower Mortality in French HIV/HCV Group - Mark Mascolini - (02/24/16) Primary Providers as Successful as Specialists in Treating HCV Infection - Mark Mascolini - (02/24/16) Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV - (02/24/16) Drug Interaction Studies Between Sofosbuvir/Velpatasvir and Boosted HIV ARV Regimens - (02/24/16) Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16) Brain Volumetric Changes After Two Years of ART Initiated During Acute HIV Infection - (02/24/16) FDG PET/CT Imaging of Lymph Nodes as a Measure of the HIV Reservoir in Humans - (02/24/16) HIV-1 Maturation Inhibitor BMS-955176: Pharmacokinetic and Exposure-Response Analysis - (02/24/16) ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment - press release - (02/24/16) A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16) Single Dose Zoledronic Acid Prevents Antiretroviral-Induced Bone Loss - (02/24/16) Recovery of bone mineral density after stopping oral HIV pre-exposure prophylaxis - (02/24/16) Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results - (02/24/16) CD8 T-Cell HIV Impact - early ART / cure / vaccine implications / Bruce Walker Opening Session - (02/24/16) Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens - press release - (02/23/16) Switching to F/TAF (Tenofovir Alafenamide) from F/TDF (Tenofovir DF) based Regimen Study 311-1089: 48-Week Data - (02/23/16) Early ART in START Trial Does Not Improve Arterial Elasticity - written by Mark Mascolini - (02/23/16) Dapivirine Vaginal Ring Cuts HIV Risk 27% to 56% in Two Trials in African Women - written by Mark Mascolini - (02/23/16)